

Trio Resources, Inc. (OTC: TRII) Acquires WALVE Biotech Pty Ltd – Cross-Border Cooperation Accelerates Health Sector Expansion in Asia

February 24, 2025, Chengdu, Sichuan, China, Trio Resources, Inc. (OTC: TRII), through its wholly-owned subsidiary Wanding Qianghua Youshang (Sichuan) Technology Co., Ltd. ("WQY"), formally signed an agreement in Malaysia to acquire 100% equity of Australian biopharmaceutical firm WALVE Biotech Pty Ltd ("WALVE Biotech"). This transaction, backed by independent third-party valuation, is expected to directly enhance TRII's financial performance upon completion.

Collaboration Framework: Synergy and Market Expansion

The agreement was signed by **Ms. Wang Ying**, Chairwoman of TRII and WQY, and **Ms. Amy Zhou**, Executive Director and CEO of WALVE Biotech. The primary objectives of this collaboration include:

- **Technology Integration:** Combining WALVE Biotech's R&D capabilities in biopharmaceuticals (e.g., drug delivery systems) with TRII's global resource network to advance novel drug development.
- **Market Expansion:** Leveraging WALVE Biotech's distribution channels in China and Southeast Asia to strengthen TRII's regional footprint.
- **Financial Growth:** Expected positive revenue impact and steady quarterly growth following the acquisition.

Strategic Impact: Global-Local Integration

This acquisition underscores TRII's commitment to deepening its presence in Asia's high-growth biopharmaceutical markets, with key advantages including:

- **Technological Edge:** WALVE Biotech's expertise in biologics complements TRII's upstream health industry capabilities.
- **Regional Synergy:** WQY's established presence in Sichuan's biopharmaceutical parks enhances resource integration.
- **Investor Confidence:** TRII's M&A-driven growth strategy is expected to strengthen its positioning in the OTC market.

Signing Ceremony: Multinational Representation

Key attendees at the signing ceremony included:

- **TRII Delegation:** Chairwoman **Ms. Wang Ying**
- **WALVE Biotech:** CEO **Ms. Amy Zhou**
- **Australian Representatives:**
 - **Dr. Li Lujiang** (Executive Director, Warifeng Biopharmaceutical)
 - **Mr. James Ho** (President, Asia Pacific International Trade Promotion Association)

- **ASEAN Leaders:**
 - **Mr. Alan Neo** (CEO, Singapore-listed HealthGate; Secretary-General, Cambodia Asia Pacific Association)
 - **Mr. Chen Youquan** (Chairman, Asia Pacific Chamber of Commerce)

The coalition highlights TRII’s political and commercial influence. Ms. Wang stated: “This merger is not just about capital integration—it unites technology, talent, and markets, serving as a catalyst for cross-border healthcare innovation.”

Future Outlook: Shareholder Value and Competitiveness

Ms. Wang Ying emphasized, “Achieving our 2025 targets will drive long-term sustainable returns for shareholders.” Analysts note that meeting these goals could enhance TRII’s valuation and financing flexibility within the OTC biotech sector.

Forward-Looking Statement

This news release includes forward-looking statements that reflect TRIO RESOURCES, INC. (TRII)'s current expectations regarding its future results, performance, prospects, and opportunities. We have identified these forward-looking statements using terms such as "may," "will," "expects," "anticipates," "believes," "intends," "estimates," and similar expressions.

These forward-looking statements are based on information currently available to TRIO RESOURCES, INC. (TRII) and are subject to a number of risks, uncertainties, and other factors that could cause actual results in 2025 and beyond to differ materially from those expressed in or implied by these forward-looking statements.

For further inquiries, please contact: baoyouqian2000@gmail.com